SCHEMBL7939797

SCHEMBL7939797

Cc1nc2c(F)cccc2nc1/C=C/c1nc(Cl)cc(N2CCCC2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 11/20 0.48
KDM4E B2RXH2 4/20 0.36
GAA P10253 4/20 0.36
L3MBTL1 Q9Y468 4/20 0.36
ACHE P22303 1/20 0.36
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GBA1 P04062 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33
NPC1 O15118 1/20 0.33
TSHR P16473 1/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7937689 0.90 PDE10A (0.49) PDE10AKDM4EGAAL3MBTL1ACHE
SCHEMBL7942725 0.86 PDE10A (0.61) PDE10AKDM4EGAAL3MBTL1ACHE
SCHEMBL7937161 0.85 PDE10A (0.51) PDE10AKDM4EGAAL3MBTL1ACHE
SCHEMBL7936495 0.81 PDE10A (0.64) PDE10AKDM4EGAAKMT2ARAB9A
SCHEMBL12574927 0.81 PDE10A (0.64) PDE10AKDM4EGAAKMT2ARAB9A
SCHEMBL7936493 0.80 PDE10A (0.49) PDE10AKDM4EGAAL3MBTL1ACHE
SCHEMBL7937698 0.79 PDE10A (0.52) PDE10AKDM4EGAAKMT2ARAB9A
SCHEMBL7937697 0.79 PDE10A (0.52) PDE10AKDM4EGAAKMT2ARAB9A
SCHEMBL7937680 0.78 PDE10A (0.55) PDE10AKDM4EGAAL3MBTL1ACHE
SCHEMBL7934257 0.77 PDE10A (0.50) PDE10AKDM4EGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-06-30 US disclosed
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-06-30 US disclosed
WO-2010027097-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE10A, PDE12, PDE9A PDE10A 1/4885KDM4E 322/4885GAA 1065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.